| Steven Borzak, MD | |
|
5401 S Congress Ave Ste 102, Atlantis, FL 33462 | |
| (561) 967-5033 | |
| Not Available |
| Full Name | Steven Borzak |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 40 Years |
| Location | 5401 S Congress Ave Ste 102, Atlantis, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427031848 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | ME82182 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jfk Medical Center | Atlantis, FL | Hospital |
| Bethesda Hospital Inc | Boynton beach, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Cardiology Group Pa | 1951304302 | 4 |
| Ecg Consultants Of Bethesda Llc | 8628134665 | 18 |
News Archive
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden"-either way, negative biopsies during active surveillance for prostate cancer are associated with excellent long-term outcomes, reports a study in The Journal of Urology®.
United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.
New research at the University of Adelaide has shed light on how many doctors are attending the funerals of their patients and the reasons behind their choice. The researchers say more needs to be done within the medical profession to openly discuss the issue.
› Verified 4 days ago
| Entity Name | Independent Ekg Consultant's, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689626756 PECOS PAC ID: 4981671740 Enrollment ID: O20040913000506 |
News Archive
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden"-either way, negative biopsies during active surveillance for prostate cancer are associated with excellent long-term outcomes, reports a study in The Journal of Urology®.
United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.
New research at the University of Adelaide has shed light on how many doctors are attending the funerals of their patients and the reasons behind their choice. The researchers say more needs to be done within the medical profession to openly discuss the issue.
› Verified 4 days ago
| Entity Name | Florida Cardiology Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558316604 PECOS PAC ID: 1951304302 Enrollment ID: O20060824000481 |
News Archive
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden"-either way, negative biopsies during active surveillance for prostate cancer are associated with excellent long-term outcomes, reports a study in The Journal of Urology®.
United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.
New research at the University of Adelaide has shed light on how many doctors are attending the funerals of their patients and the reasons behind their choice. The researchers say more needs to be done within the medical profession to openly discuss the issue.
› Verified 4 days ago
| Entity Name | Ecg Consultants Of Bethesda Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588811533 PECOS PAC ID: 8628134665 Enrollment ID: O20090227000151 |
News Archive
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden"-either way, negative biopsies during active surveillance for prostate cancer are associated with excellent long-term outcomes, reports a study in The Journal of Urology®.
United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.
New research at the University of Adelaide has shed light on how many doctors are attending the funerals of their patients and the reasons behind their choice. The researchers say more needs to be done within the medical profession to openly discuss the issue.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven Borzak, MD 7593 W Boynton Beach Blvd Ste 220, Boynton Beach, FL 33437-6162 Ph: (561) 649-7000 | Steven Borzak, MD 5401 S Congress Ave Ste 102, Atlantis, FL 33462 Ph: (561) 967-5033 |
News Archive
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden"-either way, negative biopsies during active surveillance for prostate cancer are associated with excellent long-term outcomes, reports a study in The Journal of Urology®.
United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.
New research at the University of Adelaide has shed light on how many doctors are attending the funerals of their patients and the reasons behind their choice. The researchers say more needs to be done within the medical profession to openly discuss the issue.
› Verified 4 days ago
James Heron, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #218, Atlantis, FL 33462 Phone: 561-968-0307 Fax: 561-968-7673 | |
Roberto Von Sohsten, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #102, Atlantis, FL 33462 Phone: 561-967-5033 Fax: 561-967-8974 | |
Dr. Samantha Sylvonne Kerry-ann Nicholson-spence, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-1273 | |
Alexander Chernobelsky, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #102, Atlantis, FL 33462 Phone: 561-967-5033 Fax: 561-967-8974 | |
Denzil S Seedial, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, Ste 204, Atlantis, FL 33462 Phone: 561-967-4118 Fax: 561-967-3463 | |
Dr. Daphnee Marie Hutchinson, D.O. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-1750 | |
Dr. Farahnaz Angella, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 180 Jfk Dr, Suite 311, Atlantis, FL 33462 Phone: 561-434-0353 Fax: 561-357-0869 |